
    
      There is a 28 day screening period followed by 28 day cycles (21 day cycle for the every
      three week dosing regimen, if used) . Patients will continue to receive SAR245408/SAR256212
      as long as there is clinical benefit or until a study withdrawal criterion is met. The last
      posttreatment visit will be 60 days after the last dose or until IMP-related toxicities have
      resolved or are deemed irreversible, whichever is later.
    
  